These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27086575)

  • 1. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
    Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective follow-up cardiac evaluation of children with Kawasaki disease in Northern India using the Japanese echocardiography criteria.
    Kothur K; Singh S; Sharma Y; Mittal BR
    J Cardiol; 2007 Nov; 50(5):299-307. PubMed ID: 18044459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
    Nagatomo Y; Muneuchi J; Nakashima Y; Nanishi E; Shirozu H; Watanabe M; Uike K; Nagata H; Hirata Y; Yamamura K; Takahashi Y; Okada S; Suzuki Y; Hasegawa S; Ohga S
    Int J Cardiol; 2018 Nov; 271():317-321. PubMed ID: 30144998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
    Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
    Koizumi K; Hoshiai M; Katsumata N; Toda T; Kise H; Hasebe Y; Kono Y; Sunaga Y; Yoshizawa M; Watanabe A; Kagami K; Abe M; Sugita K
    Pediatr Int; 2018 Sep; 60(9):796-802. PubMed ID: 29543362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
    Hachiya A; Kobayashi N; Matsuzaki S; Takeuchi Y; Akazawa Y; Shigemura T; Motoki N; Masumoto J; Agematsu K
    Clin Rheumatol; 2018 Jul; 37(7):1937-1943. PubMed ID: 29302828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
    Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
    Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
    Ansai H; Masuda H; Nakao H; Nishimura N; Kubota M
    Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
    Takura T; Horiuchi S
    J Cardiol; 2022 Aug; 80(2):172-178. PubMed ID: 35341683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
    Chen J; Liao J; Xiang L; Zhang S; Yan Y
    Front Immunol; 2023; 14():1237670. PubMed ID: 37936712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
    Masuda H; Kobayashi T; Hachiya A; Nakashima Y; Shimizu H; Nozawa T; Ogihara Y; Ito S; Takatsuki S; Katsumata N; Suzuki Y; Takenaka S; Hirono K; Kobayashi T; Suzuki H; Suganuma E; Takahashi K; Saji T;
    J Pediatr; 2018 Apr; 195():115-120.e3. PubMed ID: 29224935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB; Mitchell C; Beukelman T
    Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y; Kim J; Hong YM; Sohn S
    Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality in children with Kawasaki disease: 20 years of experience from a tertiary care centre in North India.
    Singh S; Bhattad S; Gupta A; Suri D; Rawat A; Rohit M
    Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S129-33. PubMed ID: 26633295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
    Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.